At GoBroad Healthcare Group, we’ve redefined the possibilities of cancer treatment through groundbreaking advancements in CAR-T cell immunotherapy. As a leader in hematologic disease and solid tumor care, our mission is to deliver innovative, patient-centric solutions that address even the most challenging cases. With specialized hospitals across Beijing, Shanghai, and Guangzhou, we combine cutting-edge science with compassionate care, offering renewed hope to patients worldwide.

Innovating CAR-T Cell Immunotherapy for Refractory Cancers

Our expertise in CAR-T cell immunotherapy has transformed outcomes for patients with relapsed or resistant cancers. Take VARELII, a Russian patient with acute B-lymphoblastic leukemia who relapsed after two failed transplants. Local doctors deemed his case incurable, but our team at Beijing GoBroad Boren Hospital saw potential. After comprehensive genetic testing revealed a BCR-ABL1 mutation not previously detected, we designed a personalized CAR-T regimen using donor-sourced CD19-targeted cells. Despite complications like cytokine release syndrome, meticulous management led to deep remission—bone marrow and cerebrospinal fluid cleared of tumor cells. Stories like VARELII’s underscore how CAR-T cell immunotherapy can bridge gaps where traditional therapies falter. Similarly, 6-year-old Tiantian achieved sustained remission from refractory Burkitt lymphoma through sequential CD19/CD20/CD22 CAR-T infusions, a pioneering approach now recognized globally. These successes highlight our commitment to expanding CAR-T cell immunotherapy applications, offering tailored strategies for diverse malignancies.

Multidisciplinary Collaboration: Precision Meets Compassion

Behind every CAR-T cell immunotherapy breakthrough is a team of specialists working in harmony. For patients like Yiyi, misdiagnosed with central nervous system relapse due to cytomegalovirus encephalitis, our experts in hematology, virology, and neurology collaborated to uncover the root cause. Antiviral therapy resolved her symptoms, allowing subsequent CAR-T treatments to achieve lasting remission. Similarly, Nawal, a Middle Eastern patient with spinal metastases, benefited from an 8-hour multidisciplinary surgery combined with targeted therapies. This integrative model ensures that CAR-T cell immunotherapy is seamlessly paired with supportive interventions, from infection control to psychological care. Our specialists, including Professor Yonghong Zhang and Director Zhao Defeng, bring decades of experience to complex cases, ensuring each treatment plan is as unique as the patient.

Beyond Remission: Lifelong Support and Global Accessibility

At GoBroad, CAR-T cell immunotherapy is just the beginning. We prioritize long-term wellness through continuous monitoring and adaptive care. Lele, an 8-year-old Hodgkin lymphoma patient, exemplifies this philosophy. After six chemotherapy cycles guided by precise staging and molecular diagnostics, he returned to school cancer-free, supported by ongoing check-ups. For international patients like Kirill, a Russian with KRAS G12C-mutated lung cancer, we bridge geographical barriers by swiftly delivering newly approved therapies—his Furazercib treatment began just 10 days post-NMPA approval. Our multilingual services and cultural sensitivity ensure seamless experiences, whether coordinating CAR-T therapies or post-transplant rehabilitation.

Conclusion

GoBroad Healthcare Group stands at the forefront of CAR-T cell immunotherapy, merging scientific rigor with unwavering empathy. From pioneering sequential CAR-T protocols to resolving complex misdiagnoses, we empower patients to reclaim their lives.